DMPK

Studying the pharmacokinetics and metabolism of your new therapeutic entities

Based on our experience in a large number of drug discovery projects, we provide an expert solution to guide the characterization of the developability of new therapeutic molecules either as stand-alone (SOLO) or within an integrated packages (DRIVE & INPACT).

Oncodesign Services offers in vitro, in life and bioanalytical components to provide complete packages for:

  • ad hoc in vitro ADME-T prediction studies
  • the design of an integrated set of in vitro and in vivo assays and
    decision trees tailored to the different stages of progression of your discovery program, from target to hit to preclinical candidate selection, and therapeutic dose prediction in humans.
  • pharmacokinetic (PK) profile and PK/PD relationship assessment
    studies in rodents (including pathological models) and other animal species (drug exposure and disease-related)
  • biodistribution (Liquid Scintillation Counting LSC or Quantitatice
    Whole Body Autoradiography QWBA) with radiolabeled test articles using radioisotopes: 3H, 14C, 125I
  • De-risking DMPK packages customized according to your data and needs
  • Introduction to non-invasive biodistribution of drugs using imaging capabilities (SPECT/TEP) in rodents, NHPs.

 

GET IN TOUCH

ADME Assays are recommended at each stage of drug discovery, to de-risk the compound in cost-effective manner.

DMPK services available from Target identification to IND filing
  • Target to hit

    Evaluation of physicochemical and in vitro ADME properties

    • Solubility
    • LogD
    • Microsomal strability
    • CYP inhibition
  • Hit to Lead

    Optimization of physicochemical and drug-like properties

    • Metabolic stability
    • CYP inhibition
    • Permeability
    • In vitro plasma protein binding
    • Combined PK-BBB
    • Unbound Partition Coefficient (Kpu,u brain)
  • Lead to candidate identification

    Optimization of drug-like properties, IVIVC, PK/PD correlation

    • Permeability
    • In vitro plasma protein binding
    • PK studies (rodents & non-rodents)
    • Target tissue exposure
    • Blood/plasma partitioning
    • Mass balance
    • PK/PD studies
    • Metabolites identification
  • Candidate selection

    Dose range finding, safety/tox evaluation, human dose prediction

    • Dose range finding (rodents & non-rodents)
    • Tissue distribution
    • Food effect
    • Metabolite profiling
    • Interspecies scoring
    • Metabolites identification
    • CYP induction